Radiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Oldroyd, S. D.
Right arrow Articles by Morcos, S. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Oldroyd, S. D.
Right arrow Articles by Morcos, S. K.

Radiology, Vol 196, 661-665, Copyright © 1995 by Radiological Society of North America

ARTICLES

Bosentan, an orally active endothelin antagonist: effect on the renal response to contrast media

SD Oldroyd, JL Haylor and SK Morcos
Sheffield Kidney Institute, Northern General Hospital, Sheffield, England.

PURPOSE: To examine the effect of bosentan, an orally active endothelin- receptor antagonist, on the renal response to contrast media in the isolated perfused rat kidney (IPRK) and to establish whether bosentan can inhibit contrast media-induced nephrotoxicity in a multiple-insult model in the conscious rat. MATERIALS AND METHODS: Renal function was measured in the IPRK (n = 24) and in the rats that had undergone unilateral nephrectomy, were maintained on a salt-free diet, and were receiving indomethacin (10 mg/kg/d; n = 60). RESULTS: In the IPRK, diatrizoate and iotrolan reduced the glomerular filtration rate and renal perfusate flow, an effect markedly inhibited by bosentan (n = 6 per group). In the multiple-insult rat model, the fall in creatinine clearance produced by diatrizoate was also markedly inhibited by bosentan (n = 15 per group). CONCLUSION: Endothelin antagonists such as bosentan may be used to reduce the prevalence of contrast-induced nephrotoxicity.


This article has been cited by other articles:


Home page
 Br. J. Radiol.Home page
S K Morcos
Ureteric obstruction and intravascular administration of contrast media: is there a risk?
Br. J. Radiol., August 1, 2003; 76(908): 564 - 565.
[Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
K. W Kenyon and J. M Nappi
Bosentan for the Treatment of Pulmonary Arterial Hypertension
Ann. Pharmacother., July 1, 2003; 37(7): 1055 - 1062.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Radiol.Home page
Y-X J Wang, Y-F Jia, K-M Chen, and S K Morcos
Radiographic contrast media induced nephropathy: experimental observations and the protective effect of calcium channel blockers
Br. J. Radiol., December 1, 2001; 74(888): 1103 - 1108.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
J. L. Haylor and S. K. Morcos
An oral ETA-selective endothelin receptor antagonist for contrast nephropathy?
Nephrol. Dial. Transplant., July 1, 2001; 16(7): 1336 - 1337.
[Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
B. K. Kramer, M. Kammerl, F. Schweda, and M. Schreiber
A primer in radiocontrast-induced nephropathy
Nephrol. Dial. Transplant., December 1, 1999; 14(12): 2830 - 2834.
[Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
J. A. DOUTHWAITE, T. S. JOHNSON, J. L. HAYLOR, P. WATSON, and A. M. E. NAHAS
Effects of Transforming Growth Factor-{beta}1 on Renal Extracellular Matrix Components and Their Regulating Proteins
J. Am. Soc. Nephrol., October 1, 1999; 10(10): 2109 - 2119.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
RADIOLOGY RADIOGRAPHICS RSNA JOURNALS ONLINE
Copyright © 1995 by the Radiological Society of North America.